Стан Мікробіоти Порожнини Товстого Кишечника У хворих На цукровий Діабет 1-Го Типу Залежно Від Тяжкості Клінічного Перебігу

Mazur, Olga; Plaksyvyi, О.H.; Pashkovska, N.V.; Bilooka, І.О.

doi:10.22141/2224-0721.5.77.2016.78756

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ендоплазматичний ретикулум (EР), поєднаний із зовнішньою мембраною ядерної оболонки, відіграє ключову роль як центральна еукаріотична мембранна органела і відповідає за синтез, згортання та дозрівання мембранних і секретованих білків, біосинтез ліпідів і зберігання кальцію. Стрес ЕР -це стан, що відіграє важливу роль у розвитку різних ССЗ, при цьому накопичення розгорнутих/неправильно згорнутих білків пов'язано з розладами ЕР, викликаними різними фізіологічними та патологічними станами [59].…”

Section: стрес ендоплазматичного ретикулумуunclassified

Product of metabolic activity of intestinal microbium trimethylamine-N-oxide (TMAO) — biomarker of progression of atherosclerosis-copy in the heart of the heart

Шишкань-Шишова

Zinych

2022

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

The literature data on the importance of intestinal microbiota as an endocrine organ — producer of biologically active metabolites, which perform key functions to maintain metabolic homeostasis of the whole organism, in particular the condition of the cardiovascular system, are analyzed. Clinical and experimental studies using a metabolomical approach have shown that the development of atherosclerotic CVD is often associated with elevated levels of one of the microbial metabolites, trimethylamine N-oxide (TMAO). TMAO may be a sensitive prognostic biomarker of complications of type 2 diabetes, including atherosclerosis and cardiovascular disease. The precursor of TMAO is trimethylamine (TMA), formed by intestinal bacteria from food phosphatidylcholine and L-carnitine. In the liver, TMA is converted to TMAO under the influence of hepatic flavin monooxygenase 3. The mechanisms of the proatherogenic effect of elevated levels of TMAO include effects on bile acid and cholesterol metabolism, platelet hyperactivation, stimulation of inflammatory processes and oxidative stress, induction of endothelial disfunction and endoplasmic reticulum stress. It has been established that TMAO, in conditions of chronic elevation, can contribute to cardiometabolic diseases. Elevated levels of TMAO in dysmetabolic conditions (obesity, type 2 diabetes, atherosclerosis, or coronary heart disease) have been suggested to be largely associated with the gut microbiota profile. Therefore, regulating the ratio of intestinal microorganisms or their ability to form a precursor of TMAO — TMA, may be a way to develop new tools for the prevention and treatment of atherosclerosis and prevent the progression of cardiovascular complications, including in patients with type 2 diabetes. Studies have shown that inhibiting various stages of TMAO production can reduce TMAO levels and help treat atherosclerosis and diabetes.

show abstract

Section: стрес ендоплазматичного ретикулумуunclassified

Product of metabolic activity of intestinal microbium trimethylamine-N-oxide (TMAO) — biomarker of progression of atherosclerosis-copy in the heart of the heart

Шишкань-Шишова

Zinych

2022

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

show abstract

Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus

Шишкань-Шишова

Zinych

Кушнарьова

et al. 2022

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Background. Type 2 diabetes mellitus is characterized by a violation of the incretin effect, in particular a decrease in the secretion of glucagon-like peptide-1 (GLP-1) by intestinal endothelial cells. In recent decades, the intestinal microbiota has been shown to play a key role in the regulation of various metabolic pathways, immune system activity, and intestinal permeability. It has been shown that the composition of bacterial genera in the intestine can unfluence the effectiveness of antidiabetic drugs (eg metformin and GLP-1 receptor agonists), which may be reduced in dysbiosis. Therefore, it is of interest to study the mechanisms that mediate the effect of microbiota on the incretin secretion. The purpose was to establish the relationship between the effects of probiotic therapy, incretin therapy and the level of endogenous GLP-1 in the serum of patients with type 2 diabetes mellitus, taking into account anthropometry and body composition. Materials and methods. We examined 23 patients with type 2 diabetes mellitus (11 women and 12 men), their average age was 56.4 ± 10.5 years (M ± SD). At the beginning of the study, the mean HbA1c level was 7.7 ± 1.5 %; all patients took metformin at an average dose of 1,500 mg/day. Patients were randomized into 2 groups: group 1 (n = 11) received a probiotic, group 2 (n = 12) — a long-acting GLP-1 receptor agonist. The concentration of GLP-1 in the blood serum was determined by the enzyme-linked immunosorbent assay, anthropometry parameters and body composition were assessed using the Tanita analyzer. Results. In the group of patients who took the probiotic, a significant increase in GLP-1 was observed, but less pronounced compared to an increase in GLP-1 level in the group of patients who took GLP-1 receptor agonists. In group 2, on the background of taking GLP-1 receptor agonists, a significant decrease in body weight, total and abdominal fat content, and a decrease in dehydration were revealed. Conclusions. An increase in the concentration of endogenous GLP-1 against the background of probiotic therapy indicates a possible positive effect of normalization of the intestinal microbiota on the secretion of endogenous incretins. The results obtained suggest that the use of a combination of probiotic and GLP-1 receptor agonists may have an additive effect on the hormonal and metabolic profile in patients with type 2 diabetes mellitus.

show abstract

Стан Мікробіоти Порожнини Товстого Кишечника У хворих На цукровий Діабет 1-Го Типу Залежно Від Тяжкості Клінічного Перебігу

Cited by 2 publications

References 15 publications

Product of metabolic activity of intestinal microbium trimethylamine-N-oxide (TMAO) — biomarker of progression of atherosclerosis-copy in the heart of the heart

Product of metabolic activity of intestinal microbium trimethylamine-N-oxide (TMAO) — biomarker of progression of atherosclerosis-copy in the heart of the heart

Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About